![Matej Mikulic](https://cdn.statcdn.com/static/../CMS/contactperson/ERI285_1713877581.png)
Top promising pipeline drugs for chronic hepatitis B, 2014, by sales
This statistic shows the top promising pipeline drugs globally for chronic hepatitis B in 2014 , by peak year sales. The peak year sales of GS-9620 (Gilead Science) drug for chronic hepatitis B was almost 385 million US dollars in the year 2014.